Effects of nasal or pulmonary delivered treatments with an adenovirus vectored interferon (mDEF201) on respiratory and systemic infections in mice caused by cowpox and vaccinia viruses.
Apr 9, 2014
The IAR serves as a contractor to the NIH for the evaluation of candidate drugs and vaccines against a number of biodefense, respiratory, and hepatitis B viruses.
Dec 11, 2013
We have determined the mechanism of death in rodents for viral encephalitides.
Sep 26, 2013
Favipiravir (T-705) shown to be highly active against prominent agents of hantavirus pulmonary syndrome.
Sep 12, 2013
Recombinant Rift Valley fever virus vaccine lacking the NSs protein may be effective as a post-exposure prophylaxis.
Jul 31, 2013
Favipiravir (T-705) shown to inhibit severe Junin virus infection and disease in a rodent model of Argentine hemorrhagic fever.
May 9, 2013
Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A (H1N1) virus infections in mice.
Nov 9, 2012
Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.
Jul 12, 2012
The ABSL-3 state-of-the-art animal facilities within the new BioInnovations building opened in the summer of 2012, greatly expanding the IAR's capacity to conduct BSL-3+, ABSL-3+ and select agent research.